NLS Pharmaceutics Unveils New Insights on Mazindol ER
NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a pioneering Swiss biopharmaceutical company focused on innovative therapies for central nervous system (CNS) disorders, is poised to share groundbreaking preclinical research on Mazindol Extended-Release (ER) at a forthcoming scientific meeting. This notable presentation will take place during the upcoming Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP).
The ASCP Annual Meeting is a significant event that brings together leading researchers and clinicians from around the globe to discuss advancements in neuropsychopharmacology. This year's event is anticipated with excitement, as it promises to provide new insights into treatment strategies for CNS conditions.
Research Highlights on Mazindol ER
The primary focus of NLS’s presentation revolves around the dual efficacy of Mazindol ER in addressing both the reward and withdrawal symptoms associated with fentanyl. The pivotal study, conducted in collaboration with Key-Obs SAS and several esteemed European academic institutions, assessed the drug's effectiveness in well-established rodent models.
Significant Findings
The preclinical findings are particularly noteworthy. In the first experiment involving conditional place preference (CPP) in C57BL/6J mice, a significant reduction in the rewarding effects of fentanyl was observed when the animals were administered Mazindol at a dose of 0.5 mg/kg. This outcome indicates that Mazindol can potentially neutralize the behavior typically associated with fentanyl exposure.
Further exploring the implications of this research, the second experiment involved Sprague-Dawley rats, where Mazindol was given at varying doses of 0.5 mg/kg and 1.0 mg/kg. The results showed a dose-dependent decrease in withdrawal symptoms, proving particularly effective against signs of agitation, salivation, and motor disturbances, which are commonly assessed using the Gellert-Holtzman scale.
Expert Insights
Dr. Jean-Charles Bizot, the Director of Research at Key-Obs SAS and the leading investigator of the KO-943 study, commented on the significance of these findings. He emphasized that Mazindol's ability to mitigate both reward and withdrawal symptoms indicates its potential as a groundbreaking therapeutic candidate for treating fentanyl dependence.
Additionally, Dr. Eric Konofal, Chief Scientific Officer of NLS Pharmaceutics, highlighted Mazindol’s unique multi-target profile, pointing to its partial mu-opioid receptor agonist properties and strong 5-HT1A receptor activity. This multi-modal approach could suggest a new avenue in addressing the challenges of opioid addiction, where conventional treatments fall short.
Implications for Treatment of CNS Disorders
Importantly, the therapeutic prospects of Mazindol extend beyond fentanyl dependence. While current ADHD medications have failed to demonstrate substantial effects on opioid withdrawal, Mazindol's efficacy prompts further investigations into its applicability in treating a range of CNS disorders. The implications of these findings could redefine treatment protocols for patients suffering from both ADHD and opioid use disorder.
Future Research Directions
The release of these compelling research results opens the door to further clinical trials, including the planned NLS-6002 study aimed at validating the efficacy of Mazindol ER in human subjects. This step is critical in determining how these animal study results translate to clinical settings.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is focused on the development of advanced therapies targeting rare and complex CNS disorders. With an innovative pipeline that includes candidates for conditions such as ADHD, narcolepsy, hypersomnia, and substance use disorders, NLS is committed to enhancing the quality of life for patients through reformulated compounds.
In summary, the research findings presented by NLS Pharmaceutics on Mazindol ER promise significant advancements in the treatment landscape for fentanyl dependence and extend potential benefits to various CNS disorders.
Frequently Asked Questions
What is Mazindol ER and its significance?
Mazindol ER is a novel formulation of Mazindol that shows promise in treating fentanyl dependence by reducing both reward and withdrawal symptoms.
What were the main findings of the study on Mazindol ER?
The study indicated that Mazindol ER effectively diminished the rewarding effects of fentanyl and alleviated withdrawal symptoms in rodent models.
Who collaborated in conducting the study?
The preclinical study was a collaborative effort between NLS Pharmaceutics and Key-Obs SAS, along with several European academic institutions.
How does Mazindol's mechanism differ from traditional treatments?
Unlike conventional ADHD medications, Mazindol functions as a multi-target agent, potentially offering a unique approach to alleviate opioid addiction.
What are the next steps for NLS Pharmaceutics?
NLS aims to initiate clinical trials, including the planned NLS-6002 study, to further explore the efficacy of Mazindol ER in human populations.
